G2-Peptide
Based on 1 Customer Validation
G2-Peptide is a 3-O-sulfated heparan sulfate (3-OS HS) binder and antiviral agent. G2-Peptide blocks herpesvirus attachment, entry, cell-to-cell spread and syncytium formation, and reduces viral protein translocation. G2-Peptide exhibits antiviral activity against both HSV-1 and HSV-2. G2-Peptide inhibits neural activity and impairs synapse assembly. G2-Peptide can be used in the research of genital herpes, ocular herpes infection and keratitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 92.54%
- CAS No.: 361443-81-4
- Formule: C90H155N13O54
- Masse moléculaire:2283.25
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
|
HSV-2 |
HSV-1 |
In Vitro
G2-Peptide (2.5-20 mg/mL; 24 h) shows no cytotoxicity to Vero cells and HCE cells at concentrations of 2.5 mg/mL or lower, while cytotoxicity occurs at higher concentrations[1].
The G2 peptide binds to discrete sites on the axonal surface of mature primary mouse hippocampal neurons[3].
The G2 peptide specifically binds to sites on mouse synaptosomes, which is confirmed by dose-dependent competition assays with unlabeled G2 peptide[3].
G2 peptide (0.1-10 μM) acutely and reversibly suppresses the electrical firing activity of mature primary mouse hippocampal neuron networks in a dose-dependent manner, achieving near-complete silencing at 10 μM[3].
G2-Peptide (2 mg/mL; 30 min) reduces the ability of HSV-2 to invade HeLa cells by approximately 80%, a result confirmed by detecting the decrease in VP16 protein levels[1].
G2-Peptide (0.15-10 mg/mL; 1 h) inhibits plaque formation of HSV-2 in Vero cells, with an IC50 of 1 mg/mL, and reaches the maximum inhibitory effect at a concentration of 2.5 mg/mL[1].
G2-Peptide (0.03125-2 mg/mL; 1 h) dose-dependently inhibits HSV-2-induced cell-cell fusion in CHO-K1 cells expressing HSV-2 entry factors[1].
G2-Peptide (0-0.25 mM; 60 min) potently inhibits HSV-1 entry into CHO-K1 cells expressing 3-OST-3, nectin-1 or HVEM, with an IC50 of 0.02-0.03 mM, and shows no cytotoxicity at concentrations up to 0.5 mM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa cells
-
Concentration:2 mg/mL
-
Incubation Time:30 min pretreatment
-
Result:Reduced VP16 protein levels by approximately 80% compared to untreated infected cells, indicating significantly reduced viral entry.
-
Cell Line:Vero cells, human corneal epithelial (HCE) cells
-
Concentration:2.5-20 mg/mL
-
Incubation Time:24 h
-
Result:Exhibited cytotoxic effects at concentrations above 2.5 mg/mL in both Vero and HCE cells, with reduced viable cell counts and altered cell morphology observed at higher concentrations.
Showed no cytotoxicity at concentrations ≤2.5 mg/mL.
In Vivo
G2-Peptide (0.5 mM) completely blocks the replication and spread of HSV-1 in mouse corneas and maintains corneal epithelial integrity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female)[1]
-
Dosage:2 mg/mL
-
Administration:intravaginal; single pretreatment dose 1 hour before infection
-
Result:Reduced average number of genital HSV-2-infected cell colonies from 15 to 1, representing a ~93% reduction.
-
Animal Model:BALB/c mice[2]
-
Dosage:0.5 mM
-
Administration:single prophylactic dose prior to viral inoculation
-
Result:Detected virtually no HSV-1 gD protein expression in corneas at 4 and 7 days post-infection.
Maintained intact corneal epithelium at both 4 and 7 days post-infection.
Chemical Information
-
CAS No. 361443-81-4
-
Appearance Solid
-
Masse moléculaire 2283.25
-
Formule C90H155N13O54
-
Color White to off-white
-
Sequence
KVA-{Asn(Galβ(1-4)GlcNAcβ(1-2)Manα(1-3)[Galβ(1-4)GlcNAcβ(1-2)Manα(1-6)]Manβ(1-4)GlcNAcβ(1-4)GlcNAc)}-KT
-
Sequence Shortening
Lys-Val-Ala-{Asn(Galβ(1-4)GlcNAcβ(1-2)Manα(1-3)[Galβ(1-4)GlcNAcβ(1-2)Manα(1-6)]Manβ(1-4)GlcNAcβ(1-4)GlcNAc)}-Lys-Thr
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
DMSO : 25 mg/mL (10.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (316 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ali MM, et al. A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells. Journal of virology. 2012 Jun;86(12):6434-43. [Content Brief]
[2]. Tiwari V, et al. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. The Journal of biological chemistry. 2011 Jul 15;286(28):25406-15. [Content Brief]
[3]. Maïza A,, et al. 3-O-sulfated heparan sulfate interactors target synaptic adhesion molecules from neonatal mouse brain and inhibit neural activity and synaptogenesis in vitro. Sci Rep. 2020 Nov 5;10(1):19114. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.4380 mL | 2.1899 mL | 4.3797 mL | 10.9493 mL |
| 5 mM | 0.0876 mL | 0.4380 mL | 0.8759 mL | 2.1899 mL | |
| 10 mM | 0.0438 mL | 0.2190 mL | 0.4380 mL | 1.0949 mL |
G2-Peptide Related Classifications
HY-P3795 Related Classifications
Powered by Bioz